IQ-AI Limited EU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING (5128M)
22 Septiembre 2021 - 12:59AM
UK Regulatory
TIDMIQAI
RNS Number : 5128M
IQ-AI Limited
22 September 2021
22 September 2021
IQ-AI Limited
("IQ-AI" or the "Company")
IQ-AI LIMITED AWARDED EU PATENT FOR DUAL-ECHO MR PERFUSION
PROCESSSING
Milwaukee - 22 September 2021: IQ-AI Limited (LSE: IQAI) (OTCQB:
IQAIF) , a developer and manufacturer of medical image processing
platforms that have led to effective therapeutic strategies that
prolong survival and improve the quality of life in brain tumor and
other patients, today announced it has been awarded a European
Patent for "Multiparameter Perfusion Imaging with Leakage
Correction".
Already patented in the USA, this technology, also referred to
loosely as "dual-echo", is a combined magnetic resonance imaging
(MRI) acquisition and post-processing technology. IQ-AI subsidiary,
Imaging Biometrics, LLC (IB), already possesses the post-processing
technology made available in IB Neuro. Standardizing the
acquisition protocols across all major vendor platforms, such as GE
Healthcare, Philips Healthcare, and Siemens Healthineers is the
final component. This work is being funded in part by a grant from
the National Institutes of Health (NIH) awarded to Principal
Investigator Dr. Charles Quarles, PhD, Professor and Chair of the
Division of Neuroimaging Research at the Barrow Neurological
Institute (Phoenix, AZ).
This technology offers the added benefit of simultaneously
generating both dynamic contrast (DSC) and dynamic contrast
enhanced (DCE) permeability parameters using a single, more
simplified, MR acquisition sequence. The acquisition protocol also
eliminates the need to administer pre-load doses of
gadolinium-based contrast agents (GBCA), resulting in a 50%
reduction in GBCA consumption for MR perfusion data acquisition.
This reduction in GBCA for DSC perfusion imaging acquisition aligns
perfectly with IQAI's recently awarded patent for 0% contrast in
standard MRI T1-weighted imaging, being developed in IB Zero
G(TM).
"This EU patent further extends our leading position in the
translation and development of novel MR Imaging technologies in
major global markets. We look forward to our continued
collaboration with Dr. Quarles, other collaborators on the grant,
and the leading scanner vendors in the industry," said Michael
Schmainda, CEO of IB.
For further information, please contact:
IQ-AI Limited
Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda
Tel: 020 7469 0930
-----------------------------------------------------------
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
-----------------------------------------------------------
About Imaging Biometrics, LLC
Imaging Biometrics(R), a subsidiary of IQ-AI Limited (LON: IQAI)
(OTCQB: IQAIF), develops and provides visualisation and analytical
solutions that enable clinicians to better diagnose and treat
disease with greater confidence. Through close collaboration with
top researchers and clinicians, sophisticated advancements are
translated into platform-independent and automated software
plug-ins which can extend the base functionality of workstations,
imaging systems, PACS, or medical viewers. By design, IB's advanced
visualisation software seamlessly integrates into routine
workflows. For more information about Imaging Biometrics, visit the
company's website at www.imagingbiometrics.com .
Safe Harbor Statement
This press release includes statements that may constitute
forward-looking statements made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements can be identified by terminology
such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates," or the negative of these words
and/or similar statements. Statements that are not historical
facts, including statements about the Company's beliefs and
expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties that could
cause actual results to differ materially from the forward-looking
statements. For example, statements about future revenues and the
Company's ability to fund its operations and contractual
obligations are forward looking and subject to risks. Several
important factors could cause actual results to differ materially
from those contained in any forward-looking statement. Potential
risks and uncertainties include, but are not limited to, the
inability to raise capital to support the Company through its
growth stage, the Company's inability to generate projected sales
and trade relations between the United States and China. The
Company does not undertake any obligation to update any
forward-looking statement, except as required under applicable
law.
Investor Relations Contact:
Michael Porter, President
Porter, LeVay & Rose, Inc.
Tel: 212-564-4700
mike@plrinvest.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDUARNRABUKUAR
(END) Dow Jones Newswires
September 22, 2021 01:59 ET (05:59 GMT)
Iq-ai (LSE:IQAI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Iq-ai (LSE:IQAI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024